Dendritic cell vaccine (melanoma), University of Pittsburgh/NCI

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDendritic cell vaccine (melanoma), University of Pittsburgh/NCI
Drug Alias NameAdVTMM2/DC
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionTyrosinase modulatorsMelanoma-associated antigen 6 modulatorsMelanoma antigen recognized by T-cells 1 modulators
TargetsTyrosinaseMelanoma-associated antigen 6Melanoma antigen recognized by T-cells 1
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of PittsburghNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of PittsburghNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A